T1	AdverseReaction 379 401	anaphylactic reactions
T2	AdverseReaction 348 366	Infusion Reactions
T3	AdverseReaction 235 245	Infections
T4	AdverseReaction 54 70	Myelosuppression
T5	AdverseReaction 332 343	Anaphylaxis
T7	AdverseReaction 534 554	Tumor Lysis Syndrome
T8	AdverseReaction 557 576	Acute renal failure
T9	AdverseReaction 581 586	death
T10	AdverseReaction 645 659	Skin Reactions
T11	AdverseReaction 710 713	SJS
T12	AdverseReaction 718 721	TEN
T13	AdverseReaction 728 733	fatal
T14	AdverseReaction 924 942	malignant diseases
T15	AdverseReaction 906 919;934 942	Pre-malignant diseases
T16	AdverseReaction 980 993	Extravasation
T17	AdverseReaction 1121 1131	Fetal harm
T18	Factor 1132 1135	can
T19	AdverseReaction 1335 1351	myelosuppression
T20	Severity 1328 1334	severe
T21	Severity 1353 1360	Grade 3
T23	Severity 1353 1358;1361 1362	Grade 4
T22	AdverseReaction 1441 1445	died
T24	AdverseReaction 1451 1493	myelosuppression-related adverse reactions
T25	AdverseReaction 1509 1527	neutropenic sepsis
T26	AdverseReaction 1529 1556	diffuse alveolar hemorrhage
T27	AdverseReaction 1570 1586	thrombocytopenia
T28	Severity 1562 1567	Grade
T29	AdverseReaction 1592 1601	pneumonia
T30	AdverseReaction 1610 1633	opportunistic infection
T31	AdverseReaction 1624 1633;1635 1638	infection CMV
T32	AdverseReaction 2330 2339	Infection
T33	AdverseReaction 2351 2360	pneumonia
T34	AdverseReaction 2362 2368	sepsis
T35	AdverseReaction 2370 2382	septic shock
T36	AdverseReaction 2388 2393	death
T37	AdverseReaction 2503 2519	myelosuppression
T38	AdverseReaction 2775 2793	Infusion reactions
T39	AdverseReaction 2865 2870	fever
T40	AdverseReaction 2872 2878	chills
T41	AdverseReaction 2880 2888	pruritus
T42	AdverseReaction 2893 2897	rash
T43	AdverseReaction 2924 2936;2955 2964	anaphylactic reactions
T44	AdverseReaction 2941 2964	anaphylactoid reactions
T45	Severity 2917 2923	severe
T46	AdverseReaction 3734 3754	Tumor lysis syndrome
T47	AdverseReaction 3968 3987	acute renal failure
T48	AdverseReaction 3992 3997	death
T49	AdverseReaction 4254 4267	skin toxicity
T50	Severity 4247 4253	severe
T51	AdverseReaction 4406 4420	Skin reactions
T52	AdverseReaction 4526 4530	rash
T53	AdverseReaction 4532 4552	toxic skin reactions
T54	AdverseReaction 4557 4574	bullous exanthema
T55	AdverseReaction 4749 4775	toxic epidermal necrolysis
T56	AdverseReaction 4777 4780	TEN
T58	AdverseReaction 4869 4893	Stevens-Johnson syndrome
T59	AdverseReaction 4895 4898	SJS
T60	AdverseReaction 4904 4907	TEN
T61	AdverseReaction 4914 4919	fatal
T62	AdverseReaction 5115 5129	skin reactions
T63	AdverseReaction 5391 5404;5419 5427	pre-malignant diseases
T64	AdverseReaction 5409 5427	malignant diseases
T65	AdverseReaction 5506 5530	myelodysplastic syndrome
T66	AdverseReaction 5532 5560	myeloproliferative disorders
T67	AdverseReaction 5562 5584	acute myeloid leukemia
T68	AdverseReaction 5589 5608	bronchial carcinoma
T69	AdverseReaction 5719 5733	extravasations
T70	AdverseReaction 5806 5814	erythema
T71	AdverseReaction 5823 5831	swelling
T72	AdverseReaction 5837 5841	pain
T73	AdverseReaction 6100 6110	fetal harm
T74	Factor 6090 6093	can
T75	Animal 6199 6203	mice
T76	Animal 6208 6212	rats
T77	AdverseReaction 6257 6280	increase in resorptions
T78	AdverseReaction 6282 6290;6304 6317	skeletal malformations
T79	AdverseReaction 6295 6317	visceral malformations
T80	AdverseReaction 6323 6351	decreased fetal body weights
T81	AdverseReaction 182 198	myelosuppression
T82	AdverseReaction 211 216	death
T83	Factor 199 202	may
T84	Severity 1353 1362	Grade 3-4
T85	AdverseReaction 2577 2587	infections
T86	Factor 2562 2573	susceptible
T87	Factor 3956 3959	may
T88	Factor 4239 4243	risk
T6	AdverseReaction 892 904	Malignancies
T57	AdverseReaction 1097 1118	Embryo-fetal toxicity
T89	Severity 5816 5822	marked
E1	AdverseReaction:T1
E2	AdverseReaction:T2
E3	AdverseReaction:T3
E4	AdverseReaction:T4
E5	AdverseReaction:T5
E7	AdverseReaction:T7
E8	AdverseReaction:T8
E9	AdverseReaction:T9
E10	AdverseReaction:T10
E11	AdverseReaction:T11
E12	AdverseReaction:T12
E13	AdverseReaction:T13
E14	AdverseReaction:T14
E15	AdverseReaction:T15
E16	AdverseReaction:T16
E17	AdverseReaction:T17 Hypothetical:E18
E18	Factor:T18
E19	AdverseReaction:T19 Effect:E20 Effect2:E23 Effect3:E21 Effect4:E84
E20	Severity:T20
E21	Severity:T21
E23	Severity:T23
E22	AdverseReaction:T22
E24	AdverseReaction:T24
E25	AdverseReaction:T25
E26	AdverseReaction:T26
E27	AdverseReaction:T27 Effect:E28
E28	Severity:T28
E29	AdverseReaction:T29
E30	AdverseReaction:T30
E31	AdverseReaction:T31
E32	AdverseReaction:T32
E33	AdverseReaction:T33
E34	AdverseReaction:T34
E35	AdverseReaction:T35
E36	AdverseReaction:T36
E37	AdverseReaction:T37
E38	AdverseReaction:T38
E39	AdverseReaction:T39
E40	AdverseReaction:T40
E41	AdverseReaction:T41
E42	AdverseReaction:T42
E43	AdverseReaction:T43 Effect:E45
E44	AdverseReaction:T44 Effect:E45
E45	Severity:T45
E46	AdverseReaction:T46
E47	AdverseReaction:T47 Hypothetical:E87
E48	AdverseReaction:T48 Hypothetical:E87
E49	AdverseReaction:T49 Effect:E50 Hypothetical:E88
E50	Severity:T50
E51	AdverseReaction:T51
E52	AdverseReaction:T52
E53	AdverseReaction:T53
E54	AdverseReaction:T54
E55	AdverseReaction:T55
E56	AdverseReaction:T56
E58	AdverseReaction:T58
E59	AdverseReaction:T59
E60	AdverseReaction:T60
E61	AdverseReaction:T61
E62	AdverseReaction:T62
E63	AdverseReaction:T63
E64	AdverseReaction:T64
E65	AdverseReaction:T65
E66	AdverseReaction:T66
E67	AdverseReaction:T67
E68	AdverseReaction:T68
E69	AdverseReaction:T69
E70	AdverseReaction:T70
E71	AdverseReaction:T71 Effect:E89
E72	AdverseReaction:T72
E73	AdverseReaction:T73 Hypothetical:E74
E74	Factor:T74
E75	Animal:T75
E76	Animal:T76
E77	AdverseReaction:T77 Hypothetical:E75 Hypothetical2:E76
E78	AdverseReaction:T78 Hypothetical:E75 Hypothetical2:E76
E79	AdverseReaction:T79 Hypothetical:E75 Hypothetical2:E76
E80	AdverseReaction:T80 Hypothetical:E75 Hypothetical2:E76
E81	AdverseReaction:T81
E82	AdverseReaction:T82 Hypothetical:E83
E83	Factor:T83
E84	Severity:T84
E85	AdverseReaction:T85 Hypothetical:E86
E86	Factor:T86
E87	Factor:T87
E88	Factor:T88
E6	AdverseReaction:T6
E57	AdverseReaction:T57
E89	Severity:T89
A1	CUI E1 C0002792
A2	UMLS-Preferred-Name E1 anaphylaxis
A3	MEDDRA-PT E1 Anaphylactic reaction
A4	MEDDRA-PT-ID E1 10002198
A5	CUI E2 C0948715
A6	UMLS-Preferred-Name E2 Infusion related reaction
A7	MEDDRA-PT E2 Infusion related reaction
A8	MEDDRA-PT-ID E2 10051792
A9	CUI E3 C3714514
A10	UMLS-Preferred-Name E3 Infection
A11	MEDDRA-PT E3 Infection
A12	MEDDRA-PT-ID E3 10021789
A13	CUI E4 C0854467
A14	UMLS-Preferred-Name E4 Myelosuppression
A15	MEDDRA-PT E4 Bone marrow failure
A16	MEDDRA-PT-ID E4 10065553
A17	LLT E4 Myelosuppression
A18	LLT-ID E4 10028584
A19	CUI E5 C0002792
A20	UMLS-Preferred-Name E5 anaphylaxis
A21	MEDDRA-PT E5 Anaphylactic reaction
A22	MEDDRA-PT-ID E5 10002198
A23	LLT E5 Anaphylaxis
A24	LLT-ID E5 10002218
A25	CUI E7 C0041364
A26	UMLS-Preferred-Name E7 Tumor Lysis Syndrome
A27	MEDDRA-PT E7 Tumour lysis syndrome
A28	MEDDRA-PT-ID E7 10045170
A29	LLT E7 Tumor lysis syndrome
A30	LLT-ID E7 10045152
A31	CUI E8 C0022660
A32	UMLS-Preferred-Name E8 Kidney Failure, Acute
A33	MEDDRA-PT E8 Acute kidney injury
A34	MEDDRA-PT-ID E8 10069339
A35	LLT E8 Acute renal failure
A36	LLT-ID E8 10001041
A37	CUI E9 C1306577
A38	UMLS-Preferred-Name E9 Death (finding)
A39	MEDDRA-PT E9 Death
A40	MEDDRA-PT-ID E9 10011906
A41	CUI E10 C0221743
A42	UMLS-Preferred-Name E10 Skin reaction
A43	MEDDRA-PT E10 Skin reaction
A44	MEDDRA-PT-ID E10 10040914
A45	CUI E11 C0038325
A46	UMLS-Preferred-Name E11 Stevens-Johnson Syndrome
A47	MEDDRA-PT E11 Stevens-Johnson syndrome
A48	MEDDRA-PT-ID E11 10042033
A49	CUI E12 C0014518
A50	UMLS-Preferred-Name E12 Toxic Epidermal Necrolysis
A51	MEDDRA-PT E12 Toxic epidermal necrolysis
A52	MEDDRA-PT-ID E12 10044223
A53	LLT E12 TEN
A54	LLT-ID E12 10043221
A55	CUI E13 C1306577
A56	UMLS-Preferred-Name E13 Death (finding)
A57	MEDDRA-PT E13 Death
A58	MEDDRA-PT-ID E13 10011906
A59	CUI E14 C0442867
A60	UMLS-Preferred-Name E14 malignant disease
A61	MEDDRA-PT E14 Neoplasm malignant
A62	MEDDRA-PT-ID E14 10028997
A63	CUI E15 C0032927
A64	UMLS-Preferred-Name E15 Precancerous Conditions
A65	MEDDRA-PT E15 Precancerous cells present
A66	MEDDRA-PT-ID E15 10049673
A67	CUI E16 C0015376
A68	UMLS-Preferred-Name E16 Extravasation
A69	MEDDRA-PT E16 Extravasation
A70	MEDDRA-PT-ID E16 10015866
A71	CUI E17 C0854268
A72	UMLS-Preferred-Name E17 Foetal damage
A73	MEDDRA-PT E17 Foetal damage
A74	MEDDRA-PT-ID E17 10016852
A75	LLT E17 Fetal damage
A76	LLT-ID E17 10054743
A77	CUI E19 C0854467
A78	UMLS-Preferred-Name E19 Myelosuppression
A79	MEDDRA-PT E19 Bone marrow failure
A80	MEDDRA-PT-ID E19 10065553
A81	LLT E19 Myelosuppression
A82	LLT-ID E19 10028584
A83	CUI E22 C1306577
A84	UMLS-Preferred-Name E22 Death (finding)
A85	MEDDRA-PT E22 Death
A86	MEDDRA-PT-ID E22 10011906
A87	CUI E24 C0854467
A88	UMLS-Preferred-Name E24 Myelosuppression
A89	MEDDRA-PT E24 Bone marrow failure
A90	MEDDRA-PT-ID E24 10065553
A91	LLT E24 Myelosuppression
A92	LLT-ID E24 10028584
A93	CUI E25 C0877153
A94	UMLS-Preferred-Name E25 Neutropenic sepsis
A95	MEDDRA-PT E25 Neutropenic sepsis
A96	MEDDRA-PT-ID E25 10049151
A97	CUI E26 C0852879
A98	UMLS-Preferred-Name E26 Pulmonary Alveolar Hemorrhage
A99	MEDDRA-PT E26 Pulmonary alveolar haemorrhage
A100	MEDDRA-PT-ID E26 10037313
A101	LLT E26 Pulmonary alveolar hemorrhage
A102	LLT-ID E26 10037314
A103	CUI E27 C0040034
A104	UMLS-Preferred-Name E27 Thrombocytopenia
A105	MEDDRA-PT E27 Thrombocytopenia
A106	MEDDRA-PT-ID E27 10043554
A107	CUI E29 C0032285
A108	UMLS-Preferred-Name E29 Pneumonia
A109	MEDDRA-PT E29 Pneumonia
A110	MEDDRA-PT-ID E29 10035664
A111	CUI E30 C0029118
A112	UMLS-Preferred-Name E30 Opportunistic Infections
A113	MEDDRA-PT E30 Opportunistic infection
A114	MEDDRA-PT-ID E30 10030901
A115	CUI E31 C0010823
A116	UMLS-Preferred-Name E31 Cytomegalovirus Infections
A117	MEDDRA-PT E31 Cytomegalovirus infection
A118	MEDDRA-PT-ID E31 10011831
A119	LLT E31 CMV infection
A120	LLT-ID E31 10009703
A121	CUI E32 C3714514
A122	UMLS-Preferred-Name E32 Infection
A123	MEDDRA-PT E32 Infection
A124	MEDDRA-PT-ID E32 10021789
A125	CUI E33 C0032285
A126	UMLS-Preferred-Name E33 Pneumonia
A127	MEDDRA-PT E33 Pneumonia
A128	MEDDRA-PT-ID E33 10035664
A129	CUI E34 C0243026
A130	UMLS-Preferred-Name E34 Sepsis
A131	MEDDRA-PT E34 Sepsis
A132	MEDDRA-PT-ID E34 10040047
A133	CUI E35 C0036983
A134	UMLS-Preferred-Name E35 Septic Shock
A135	MEDDRA-PT E35 Septic shock
A136	MEDDRA-PT-ID E35 10040070
A137	CUI E36 C1306577
A138	UMLS-Preferred-Name E36 Death (finding)
A139	MEDDRA-PT E36 Death
A140	MEDDRA-PT-ID E36 10011906
A141	CUI E37 C0854467
A142	UMLS-Preferred-Name E37 Myelosuppression
A143	MEDDRA-PT E37 Bone marrow failure
A144	MEDDRA-PT-ID E37 10065553
A145	LLT E37 Myelosuppression
A146	LLT-ID E37 10028584
A147	CUI E38 C0948715
A148	UMLS-Preferred-Name E38 Infusion related reaction
A149	MEDDRA-PT E38 Infusion related reaction
A150	MEDDRA-PT-ID E38 10051792
A151	CUI E39 C0015967
A152	UMLS-Preferred-Name E39 Fever
A153	MEDDRA-PT E39 Pyrexia
A154	MEDDRA-PT-ID E39 10037660
A155	LLT E39 Fever
A156	LLT-ID E39 10016558
A157	CUI E40 C0085593
A158	UMLS-Preferred-Name E40 Chills
A159	MEDDRA-PT E40 Chills
A160	MEDDRA-PT-ID E40 10008531
A161	CUI E41 C0033774
A162	UMLS-Preferred-Name E41 Pruritus
A163	MEDDRA-PT E41 Pruritus
A164	MEDDRA-PT-ID E41 10037087
A165	CUI E42 C0015230
A166	UMLS-Preferred-Name E42 Exanthema
A167	MEDDRA-PT E42 Rash
A168	MEDDRA-PT-ID E42 10037844
A169	CUI E43 C0002792
A170	UMLS-Preferred-Name E43 anaphylaxis
A171	MEDDRA-PT E43 Anaphylactic reaction
A172	MEDDRA-PT-ID E43 10002198
A173	CUI E44 C0340865
A174	UMLS-Preferred-Name E44 Anaphylactoid reaction
A175	MEDDRA-PT E44 Anaphylactoid reaction
A176	MEDDRA-PT-ID E44 10002216
A177	CUI E46 C0041364
A178	UMLS-Preferred-Name E46 Tumor Lysis Syndrome
A179	MEDDRA-PT E46 Tumour lysis syndrome
A180	MEDDRA-PT-ID E46 10045170
A181	LLT E46 Tumor lysis syndrome
A182	LLT-ID E46 10045152
A183	CUI E47 C0022660
A184	UMLS-Preferred-Name E47 Kidney Failure, Acute
A185	MEDDRA-PT E47 Acute kidney injury
A186	MEDDRA-PT-ID E47 10069339
A187	LLT E47 Acute renal failure
A188	LLT-ID E47 10001041
A189	CUI E48 C1306577
A190	UMLS-Preferred-Name E48 Death (finding)
A191	MEDDRA-PT E48 Death
A192	MEDDRA-PT-ID E48 10011906
A193	CUI E49 C1167791
A194	UMLS-Preferred-Name E49 Skin toxicity
A195	MEDDRA-PT E49 Skin toxicity
A196	MEDDRA-PT-ID E49 10059516
A197	CUI E51 C0221743
A198	UMLS-Preferred-Name E51 Skin reaction
A199	MEDDRA-PT E51 Skin reaction
A200	MEDDRA-PT-ID E51 10040914
A201	CUI E52 C0015230
A202	UMLS-Preferred-Name E52 Exanthema
A203	MEDDRA-PT E52 Rash
A204	MEDDRA-PT-ID E52 10037844
A205	CUI E53 C0521465
A206	UMLS-Preferred-Name E53 Toxicoderma
A207	MEDDRA-PT E53 Toxic skin eruption
A208	MEDDRA-PT-ID E53 10057970
A209	LLT E53 Toxicoderma
A210	LLT-ID E53 10044259
A211	CUI E54 C0235819
A212	UMLS-Preferred-Name E54 Rash bullous
A213	MEDDRA-PT E54 Dermatitis bullous
A214	MEDDRA-PT-ID E54 10012441
A215	LLT E54 Rash bullous
A216	LLT-ID E54 10037852
A217	CUI E55 C0014518
A218	UMLS-Preferred-Name E55 Toxic Epidermal Necrolysis
A219	MEDDRA-PT E55 Toxic epidermal necrolysis
A220	MEDDRA-PT-ID E55 10044223
A221	CUI E56 C0014518
A222	UMLS-Preferred-Name E56 Toxic Epidermal Necrolysis
A223	MEDDRA-PT E56 Toxic epidermal necrolysis
A224	MEDDRA-PT-ID E56 10044223
A225	LLT E56 TEN
A226	LLT-ID E56 10043221
A227	CUI E58 C0038325
A228	UMLS-Preferred-Name E58 Stevens-Johnson Syndrome
A229	MEDDRA-PT E58 Stevens-Johnson syndrome
A230	MEDDRA-PT-ID E58 10042033
A231	CUI E59 C0038325
A232	UMLS-Preferred-Name E59 Stevens-Johnson Syndrome
A233	MEDDRA-PT E59 Stevens-Johnson syndrome
A234	MEDDRA-PT-ID E59 10042033
A235	CUI E60 C0014518
A236	UMLS-Preferred-Name E60 Toxic Epidermal Necrolysis
A237	MEDDRA-PT E60 Toxic epidermal necrolysis
A238	MEDDRA-PT-ID E60 10044223
A239	LLT E60 TEN
A240	LLT-ID E60 10043221
A241	CUI E61 C1306577
A242	UMLS-Preferred-Name E61 Death (finding)
A243	MEDDRA-PT E61 Death
A244	MEDDRA-PT-ID E61 10011906
A245	CUI E62 C0221743
A246	UMLS-Preferred-Name E62 Skin reaction
A247	MEDDRA-PT E62 Skin reaction
A248	MEDDRA-PT-ID E62 10040914
A249	CUI E63 C0032927
A250	UMLS-Preferred-Name E63 Precancerous Conditions
A251	MEDDRA-PT E63 Precancerous cells present
A252	MEDDRA-PT-ID E63 10049673
A253	CUI E64 C0442867
A254	UMLS-Preferred-Name E64 malignant disease
A255	MEDDRA-PT E64 Neoplasm malignant
A256	MEDDRA-PT-ID E64 10028997
A257	CUI E65 C3463824
A258	UMLS-Preferred-Name E65 MYELODYSPLASTIC SYNDROME
A259	MEDDRA-PT E65 Myelodysplastic syndrome
A260	MEDDRA-PT-ID E65 10028533
A261	CUI E66 C0027022
A262	UMLS-Preferred-Name E66 Myeloproliferative disease
A263	MEDDRA-PT E66 Myeloproliferative disorder
A264	MEDDRA-PT-ID E66 10028576
A265	CUI E67 C0023467
A266	UMLS-Preferred-Name E67 Leukemia, Myelocytic, Acute
A267	MEDDRA-PT E67 Acute myeloid leukaemia
A268	MEDDRA-PT-ID E67 10000880
A269	LLT E67 Acute myeloid leukemia
A270	LLT-ID E67 10000886
A271	CUI E68 C0007121
A272	UMLS-Preferred-Name E68 Bronchogenic Carcinoma
A273	MEDDRA-PT E68 Bronchial carcinoma
A274	MEDDRA-PT-ID E68 10006417
A275	CUI E69 C0015376
A276	UMLS-Preferred-Name E69 Extravasation
A277	MEDDRA-PT E69 Extravasation
A278	MEDDRA-PT-ID E69 10015866
A279	CUI E70 C0041834
A280	UMLS-Preferred-Name E70 Erythema
A281	MEDDRA-PT E70 Erythema
A282	MEDDRA-PT-ID E70 10015150
A283	CUI E71 C0038999
A284	UMLS-Preferred-Name E71 Swelling
A285	MEDDRA-PT E71 Swelling
A286	MEDDRA-PT-ID E71 10042674
A287	CUI E72 C0030193
A288	UMLS-Preferred-Name E72 Pain
A289	MEDDRA-PT E72 Pain
A290	MEDDRA-PT-ID E72 10033371
A291	CUI E73 C0854268
A292	UMLS-Preferred-Name E73 Foetal damage
A293	MEDDRA-PT E73 Foetal damage
A294	MEDDRA-PT-ID E73 10016852
A295	LLT E73 Fetal damage
A296	LLT-ID E73 10054743
A297	flag E77 unmapped
A298	CUI E77 C0015951
A299	UMLS-Preferred-Name E77 Fetal Resorption
A300	CUI E78 C0795693
A301	UMLS-Preferred-Name E78 Skeletal malformation
A302	MEDDRA-PT E78 Congenital musculoskeletal anomaly
A303	MEDDRA-PT-ID E78 10062344
A304	LLT E78 Skeletal malformation
A305	LLT-ID E78 10040771
A306	CUI E79 C3808677
A307	UMLS-Preferred-Name E79 Visceral malformations
A308	MEDDRA-PT E79 Gastrointestinal malformation
A309	MEDDRA-PT-ID E79 10061596
A310	CUI E80 C0015934
A311	UMLS-Preferred-Name E80 Fetal Growth Retardation
A312	MEDDRA-PT E80 Foetal growth restriction
A313	MEDDRA-PT-ID E80 10070531
A314	LLT E80 Fetal growth restriction
A315	LLT-ID E80 10070532
A316	CUI E81 C0854467
A317	UMLS-Preferred-Name E81 Myelosuppression
A318	MEDDRA-PT E81 Bone marrow failure
A319	MEDDRA-PT-ID E81 10065553
A320	LLT E81 Myelosuppression
A321	LLT-ID E81 10028584
A322	CUI E82 C1306577
A323	UMLS-Preferred-Name E82 Death (finding)
A324	MEDDRA-PT E82 Death
A325	MEDDRA-PT-ID E82 10011906
A326	CUI E85 C3714514
A327	UMLS-Preferred-Name E85 Infection
A328	MEDDRA-PT E85 Infection
A329	MEDDRA-PT-ID E85 10021789
A330	CUI E6 C0006826
A331	UMLS-Preferred-Name E6 Malignant Neoplasms
A332	MEDDRA-PT E6 Neoplasm malignant
A333	MEDDRA-PT-ID E6 10028997
A334	CUI E57 C0270009
A335	UMLS-Preferred-Name E57 Fetal or neonatal effect of toxic substance transmitted via placenta and/or breast milk
A336	MEDDRA-PT E57 Maternal drugs affecting foetus
A337	MEDDRA-PT-ID E57 10026923
A338	LLT E57 Drug toxicity NEC affecting foetus
A339	LLT-ID E57 10013750
